Harmonic Discovery Analysis: $8M Raised
What is Harmonic Discovery?
Harmonic Discovery develops machine-learning tools for next-generation medicines with precision pharmacology. Its platform combines structural bioinformatics, generative chemistry, and curated multimodal data to design molecules that bind intended targets while avoiding anti-targets. The company cites peer-reviewed work in Nature Communications, Bioinformatics Advances, PNAS, and arXiv, and operates from New York, Helsinki, and Tucson.
Location
New York, New York, United States
Employees
1-10
Founded
2021
Revenue
$0-5M
Product Features & Capabilities
- Engineering precision pharmacology, generative chemistry platform, multi-targeted drug discovery, integration of bioactivity data types, rational drug design.
How much Harmonic Discovery raised
Seed - $8 million
September 8, 2022Lead Investor: Innovation Endeavors, Fifty Years, Y Combinator, and other select investors.
Who are the founders of Harmonic Discovery
Business Model
Business model involves partnerships; revenue from licensing agreements and direct sales.
Market Focus
Harmonic Discovery primarily focuses on the biotechnology and pharmaceutical industry, specifically in the development of next-generation medicines using machine learning and precision pharmacology.
Investors
- Innovation Endeavors
- Fifty Years
- Y Combinator
- Boom Capital
- Caffeinated Capital
Competitors Overview
Harmonic Discovery operates in the field of precision pharmacology and machine learning for drug development. Its main competitors include:
-
Deciphera Pharmaceuticals: This biopharmaceutical company focuses on developing new medicines for cancer treatment. They utilize a unique approach to target key mechanisms of tumor resistance, which may provide them an edge in addressing complex cancer types. Their pipeline includes several promising candidates aimed at various cancers.
-
Valerio Therapeutics: A clinical-stage biotechnology company that specializes in DNA decoy therapeutics. They focus on intracellular DNA-binding targets, which allows them to develop first-in-class treatments for oncology and inflammatory diseases. Their innovative approach to targeting DNA functions may differentiate them in the market.
-
Kite Pharma: Known for its pioneering work in CAR T-cell therapy, Kite Pharma develops cancer immunotherapy products. Their focus on genetically engineered cell therapies positions them uniquely in the immuno-oncology space, providing a different therapeutic approach compared to Harmonic Discovery's precision pharmacology.
-
Immunophotonics: This company is focused on Interventional Immuno-Oncology, developing novel treatments for solid tumors. Their innovative approach to combining immunotherapy with interventional techniques may offer distinct advantages in treating certain cancer types.
-
Oncodesign Precision Medicine: Specializing in precision medicine, Oncodesign aims to provide effective diagnostic and therapeutic solutions for resistant and metastatic cancers. Their focus on personalized medicine and resistance mechanisms may provide them with a competitive edge in the oncology market.
These competitors each have unique technologies and approaches that differentiate them from Harmonic Discovery, particularly in their focus areas and therapeutic strategies.
See something that needs updating? Suggest edits to this profile.